Misako Higashida-Konishi

Dr. Misako Higashida-Konishi

National Hospital Organization Tokyo Medical Center
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KIKeisuke Izumi
Keisuke Izumi
OMOkinori Murata
Okinori Murata
MHMisako Higashida-Konishi
Misako Higashida-Konishi
YKYuko Kaneko
Yuko Kaneko
HOHisaji Oshima
Hisaji Oshima
TTTsutomu Takeuchi
Tsutomu Takeuchi
Polymyalgia rheumatica (PMR) is an inflammatory disorder characterized by pain and stiffness in the shoulders, hips, and proximal limbs; it usually affects elderly patients. The effectiveness of methotrexate and tocilizumab in PMR treatment has not been extensively studied. Thus, we aimed to assess the steroid-sparing effect of tocilizumab and methotrexate in PMR in clinical practice. Consecutive patients with PMR in our hospitals, who were included in our retrospective cohort, were reviewed between 2005 and 2015 and divided into the following groups according to their treatments: prednisolone or none (prednisolone group), methotrexate ± prednisolone (methotrexate group), or tocilizumab ± prednisolone (tocilizumab group). The prednisolone dose at the last follow-up was compared. A total of 227 patients with an average age of 74 years were enrolled. No difference in baseline characteristics was found among the three groups. The prednisolone dose at the last follow-up was lower (0 vs. 3.0 vs. 3.5 mg/day, p < 0.001) and the prednisolone discontinuation rate was higher (80.0% vs. 28.3% vs. 18.8%, p < 0.0001) in the tocilizumab group than in the prednisolone and methotrexate groups. This study suggested that tocilizumab has a steroid-sparing effect in PMR. Tocilizumab can be an option in the management of PMR. Future studies are warranted to confirm our findings.

30 April 2020 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
MHMisako Higashida-Konishi
Misako Higashida-Konishi
KIKeisuke Izumi
Keisuke Izumi
MTMasako Tsukamoto
Masako Tsukamoto
HOHiroaki Ohya
Hiroaki Ohya
NTNozomi Takasugi
Nozomi Takasugi
HOHisaji Oshima
Hisaji Oshima

24 September 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MHMisako Higashida-Konishi
Misako Higashida-Konishi
MAMitsuhiro Akiyama
Mitsuhiro Akiyama
TSTatsuya Shimada
Tatsuya Shimada
SHSatoshi Hama
Satoshi Hama
TOTatsuhiro Oshige
Tatsuhiro Oshige
YOYutaka Okano
Yutaka Okano

9 August 2021 in International Journal of Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SHSatoshi Hama
Satoshi Hama
MAMitsuhiro Akiyama
Mitsuhiro Akiyama
TSTatsuya Shimada
Tatsuya Shimada
MHMisako Higashida-Konishi
Misako Higashida-Konishi
HTHiroshi Takei
Hiroshi Takei
YOYutaka Okano
Yutaka Okano
Click on the article title to read more.

5 July 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
TSTatsuya Shimada
Tatsuya Shimada
MHMisako Higashida-Konishi
Misako Higashida-Konishi
MAMitsuhiro Akiyama
Mitsuhiro Akiyama
SHSatoshi Hama
Satoshi Hama
HTHiroshi Takei
Hiroshi Takei
YOYutaka Okano
Yutaka Okano

27 January 2023 in World Allergy Organization Journal
Verified
Journal Article
Open access
MHMisako Higashida-Konishi
Misako Higashida-Konishi
KIKeisuke Izumi
Keisuke Izumi
TSTatsuya Shimada
Tatsuya Shimada
SHSatoshi Hama
Satoshi Hama
TOTatsuhiro Oshige
Tatsuhiro Oshige
YOYutaka Okano
Yutaka Okano
This study aimed to evaluate the prevalence of allergic disorders in patients with primary Sjögren's syndrome (pSS), compare it with that of patients with rheumatoid arthritis (RA), and examine the risk factors in patients with pSS. We retrospectively examined the records of patients diagnosed with pSS and RA who regularly visited our department between 2010 and 2020. Allergic disorders included drug allergy, food allergy, allergic contact dermatitis (ACD), allergic rhinitis (AR)/allergic conjunctivitis (AC), and asthma. Patients with pSS (292 patients) had a higher prevalence of food allergy, drug allergy, and AR/AC than those with RA (413 patients). The multivariate analysis revealed that patients with pSS who had drug allergy had a higher prevalence of food allergy, higher eosinophil levels, and higher positivity rates of anti-SS-related antigen A (SSA) antibodies than those without drug allergy; those with food allergy had a higher rate of ACD than those without food allergy and vice versa; those with AR/AC had a higher rate of ACD and asthma and higher eosinophil levels than those without AR/AC; those with asthma had a higher rate of AR/AC than those without asthma. Patients with pSS had a higher prevalence of allergic disorders than those with RA. Among patients with pSS, the risk factors for drug allergy were food allergy, higher eosinophil levels, and positivity for anti-SSA antibodies, the risk factor for food allergy was ACD and vice versa, the risk factors for AR/AC were ACD, asthma, and high eosinophil levels, and the risk factor for asthma was AR/AC.